Skip to main content

Table 4 Clinical adverse effects

From: Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC)

  Overall H101 Control P value
Fever     0.023
  > 38.5 °C 55.4 % 64.4 % 46.6 %  
  ≤ 38.5 °C 44.6 % 35.6 % 53.4 %  
Pain     0.875
 Yes 65.1 % 64.4 % 65.9 %  
 No 34.9 % 35.6 % 34.1 %  
Ascites     0.864
 Yes 25.7 % 26.4 % 25 %  
 No 74.3 % 73.6 % 75 %  
Acute renal failure     
 Yes 5.1 % 5.7 % 4.5 % 0.896
 No 94.9 % 94.3 % 95.5 %  
Encephalopathy     
 Yes 0 0 0  
 No 100 % 100 % 100 %  
White Blood Cell     
 Before TACE 5.7 6.0 5.5 0.369
 After TACE 7.64 7.0 8.84 0.991
 Elevation 1.61 0.5 2.97 0.001
PLT     
 Before 167.0 179.2 154.5 0.186
 After 113.0 122.8 106.1 0.258
 Elevation 49.0 52.7 48.4 0.480
ALT     
 Before 41.5 43.2 41.4 0.371
 After 167.1 153.0 200.9 0.405
 Elevation 103.1 88.1 118.4 0.480
AST     
 Before 50.9 57.1 46.4 0.249
 After 221.3 225.4 213.5 0.993
 Elevation 154.2 141.2 162.0 0.863
TBIL     
 Before 16.3 16.1 16.8 0.657
 After 30.4 28.3 31.8 0.162
 Elevation 12.9 12.4 13.25 0.413
ALB     
 Before 40.0 38.2 41.2 0.161
 After 35.4 34.1 37.0 0.314
 Elevation 4.1 3.6 4.4 0.226
  1. PLT platelet count, ALB albumin, ALT alanine aminotransferase, AST aspartate aminotransferase, PLT platelet, TACE transhepatic arterial chemoembolization, TBIL total bilirubin